Priorities & Actions
Parkinson's Plan 2006
Parkinson's Matrix
Research Agenda

Research Resources
Animal Models
Antibody Resources
Clinical Research
Gene Therapy
Genetic Resources
Brain Banks Across the
   United States

Funding Research
Funding Announcements
Clinical Trials
Related Literature

Research Centers
NIH Intramural Research
Udall Centers of
   Excellence

Patient/Caregiver Information
Parkinson's Disease
PD Clinical Trials

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Join our electronic mailing list

---

Summary of the article by Dr. Greenamyre on pesticides and Parkinson's Disease

In the December issue of Nature Neuroscience, Emory University neurologist Tim Greenamyre and colleagues showed that rotenone, a commonly used organic pesticide, can induce the major features of Parkinson's disease in rats. These results provide not only a new animal model for testing potential treatments, but they also support the idea that chronic exposure to environmental pesticides may contribute to the incidence of Parkinson's in humans.

Parkinson's disease is characterized by rigidity, bradykinesia (reduced movement) and tremors, which are caused by the progressive degeneration of dopamine-containing neurons in a brain region called the substantia nigra. Another characteristic feature of the disease is that the neurons of Parkinson's patients contain abnormal protein deposits known as "Lewy bodies." Although some cases of Parkinson's can be attributed to clear-cut genetic factors, the majority of cases are still unexplained; these so-called "sporadic" cases have been proposed to result from a combination of genetic susceptibility and environmental factors.

Before this study, the most realistic animal model of Parkinson's was the so-called MPTP model, in which mice or monkeys are treated with a drug known as 1, 2, 3, 6-tetrahydropyridine (MPTP). This model originates from the early 1980s, when a number of heroin addicts developed sudden and irreversible symptoms of parkinsonism after injecting themselves with an illicit drug preparation contaminated by MPTP. The reason for the toxic effect is that MPTP (or, more strictly, its derivative MPP+) inhibits one of the enzymes in mitochondria, which are the intracellular organelles that provide cells with energy. This led scientists to wonder whether this mitochondrial enzyme - "complex I" - was defective in Parkinson's patients. Several laboratories then found that complex I was defective not only in the brains, but also throughout the bodies, of people with Parkinson's disease.

Rotenone, like several other pesticides, inhibits complex I, and its chemical structure allows it to have toxic effects throughout the body. So Greenamyre and colleagues hypothesized that chronic treatment with low levels of rotenone might cause the same "systemic" complex I defect seen in Parkinson's patients and thereby produce parkinsonian symptoms in rats.

They administered rotenone intravenously over a period of several weeks and observed gradual degeneration of the dopamine neurons, accompanied by behavioral features of parkinsonism and the formation of structures that closely resemble Lewy bodies. A likely explanation, Greenamyre speculated, is that rotenone acts by caused the mitochondria to produce free radicals, reactive chemicals that produce oxidative damage to cells and which have been implicated in many human degenerative diseases.

Rotenone is a naturally occurring pesticide and is widely used both as an insecticide and as a method for killing fish (as part of water management programs). It is considered relatively benign compared to many other pesticides. Although the new study does not prove that rotenone causes parkinsonism in humans, it is likely to raise new questions about rotenone's safety. More generally, it lends credence to the idea that chronic exposure to environmental toxins, including pesticides, may contribute to the incidence of the disease. Determining to what extent pesticide exposure can account for parkinsonism will require a great deal of further laboratory research and epidemiological study. The present findings, however, are consistent with the idea that chronic exposure to low levels of environmental toxin may cause cumulative damage to the brain's dopamine system, eventually leading to the clinical symptoms of the disease.

Betarbet, R, Sherer, TB, MacKenzie, G, Garcia-Osuna, M, Panov, AV and Greenamyre, JT, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nature Neuroscience 3:1301-1306, 2000

Last updated February 09, 2005